{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T06:20:53Z","timestamp":1781418053838,"version":"3.54.1"},"reference-count":158,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Drug resistant tuberculosis is a major public health concern, since the causative agent Mycobacterium tuberculosis is resistant to the most effective drugs against tuberculosis treatment ie., rifampicin and isoniazid. Globally, it accounts 4.6 percent of the patients with tuberculosis, but in some low socioeconomic areas this proportion exceeds to 25 percent. The treatment of drug resistant tuberculosis is prolonged (9-12 months) and often have less favorable outcome with novel as well as recently repurposed drugs administered by conventional routes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Clinically, these repurposed drugs have shown several major concerns including low penetration of the drugs to the pulmonary region, emergence of resistant forms, first pass effects, drug-drug interactions, food effects, and serious side effects upon administration by conventional route of administration. Although, several antimicrobial agents have been either approved or are under investigation at different stages of clinical trials and in pre-clinical studies via inhalation route for the treatment of respiratory infections, inhalable formulation for the treatment of drug resistant tuberculosis is most untouched aspect of drug delivery to validate clinically. Only a single dry powder inhalation formulation of capreomycin is able to reach the milestone, ie., phase I for the treatment of drug resistant tuberculosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Administering inhalable formulations of repurposed drugs as adjuvant in the treatment of drug resistant tuberculosis could mitigate several concerns by targeting drugs directly in the vicinity of bacilli.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This review focuses on the limitations and major concerns observed during clinical trials of repurposed drugs (host directed or bactericidal drugs) administered conventionally for the treatment of drug resistant tuberculosis. The outcomes and the concerns of these clinical trials rationalized the need of repurposing formulation which could be administered by inhalation route as adjunctive treatment of drug resistant tuberculosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jamp.2024.0051","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T04:08:51Z","timestamp":1733717331000},"page":"149-167","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Prospects of Inhalable Formulations of Conventionally Administered Repurposed Drugs for Adjunctive Treatment of Drug-Resistant Tuberculosis: Supporting Evidence from Clinical Trials and Cohort Studies"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9211-8329","authenticated-orcid":false,"given":"Rajeev","family":"Ranjan","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Gopal Narayan Singh University, Sasaram, Bihar, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Siva Reddy","family":"Devireddy","sequence":"additional","affiliation":[{"name":"Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01740-y"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30428-4"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01065-y"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9090550"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1976OC"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201964"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00753-13"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02175-15"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.12.2798"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01956-19"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70053-8"},{"key":"e_1_3_5_13_2","unstructured":"NIH. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (Non-CF BE). ClinicalTrialsGov; 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01764841 [Last accessed: November5 2024]."},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbr.2012.07.012"},{"key":"e_1_3_5_15_2","unstructured":"ClinicalTrials.gov. Nebulized ceftazidime and amikacin in ventilator associated pneumonia. U S Natl Libr Med; 2008. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00786305 [Last accessed: November5 2024]."},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky239"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S51303"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02346-12"},{"key":"e_1_3_5_19_2","unstructured":"Nessel J. Itraconazole inhalation receives IND approval for phase 2 clinical trial. Pharm Times; 2019. Available from: https:\/\/www.pharmacytimes.com\/resource-centers\/asthma\/itraconazole-inhalation-receives-ind-approval-for-phase-2-clinical-trial [Last accessed: November5 2024]."},{"key":"e_1_3_5_20_2","unstructured":"Mattes G. TFF pharmaceuticals announces initiation of phase 1 clinical trial of voriconazole inhalation powder to treat invasive pulmonary aspergillosis (IPA). BioSpace; 2019. Available from: https:\/\/www.biospace.com\/article\/tff-pharmaceuticals-announcesinitiation-of-phase-1-clinical-trial-of-voriconazole-inhalation-powder-to-treat-invasive-pulmonary-aspergillosis-ipa-\/ [Last accessed: November5 2024]."},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2007.01.008"},{"key":"e_1_3_5_22_2","unstructured":"NIH. A randomized controlled trial of inhaled amphotericin B for maintaining remission in allergic bronchopulmonary aspergillosis. ClinicalTrialsGov. 2013. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01857479 [Last accessed: November5 2024]."},{"key":"e_1_3_5_23_2","unstructured":"ClinicalTrials.gov. Study evaluating fosfomycin\/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas aeruginosa lung infection. U S Natl Libr Med. 2013. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00794586 [Last accessed: November5 2024]."},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/jor1020015"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3211"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2017.1379"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2018.1460"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2015.05.021"},{"issue":"1","key":"e_1_3_5_29_2","article-title":"Development of dry powder inhaler containing prothionamide-PLGA nanoparticles optimized through statistical design: In-vivo study","volume":"4","author":"Debnath SK","year":"2017","unstructured":"Debnath SK, , Srinivasan S, , Debnath M. Development of dry powder inhaler containing prothionamide-PLGA nanoparticles optimized through statistical design: In-vivo study. Nanomed. J, 2017; 4(1).","journal-title":"Nanomed. J"},{"issue":"1","key":"e_1_3_5_30_2","first-page":"20","article-title":"Validated UV-spectrophotometric method for the ethionamide estimation in bulk, tablet and nanoparticles","volume":"9","author":"Debnath SK","year":"2017","unstructured":"Debnath SK, , Saisivam S, , Debnath M. Validated UV-spectrophotometric method for the ethionamide estimation in bulk, tablet and nanoparticles. Int J Drug Dev & Res, 2017; 9(1):20\u201323.","journal-title":"Int J Drug Dev & Res"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.05.052"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00099-19"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2014.1187"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.05.024"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00690"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2021.102081"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2010.0855"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.05.003"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP40221"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP40213"},{"issue":"6","key":"e_1_3_5_41_2","first-page":"349","article-title":"Low incidence of hypercalcaemia in tuberculosis in Malaysia","volume":"96","author":"Tan T","year":"1993","unstructured":"Tan T, , Lee B, , Khalid B. Low incidence of hypercalcaemia in tuberculosis in Malaysia. Am. J. Trop. Med. Hyg, 1993; 96(6):349\u2013351.","journal-title":"Am. J. Trop. Med. Hyg"},{"issue":"2","key":"e_1_3_5_42_2","first-page":"869","article-title":"Are tuberculous patients at a great risk from hypercalcemia","volume":"69","author":"Fuss M","year":"1988","unstructured":"Fuss M, , Karmali R, , Pepersack T, et al. Are tuberculous patients at a great risk from hypercalcemia? QJM: Int. J. Med, 1988; 69(2):869\u2013878.","journal-title":"QJM: Int. J. Med"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065835"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024363"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1801OC"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24574"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.6.2062-2069.1996"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1086\/589515"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121497109"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.11.90"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-93-4-585"},{"issue":"11","key":"e_1_3_5_52_2","first-page":"694","article-title":"Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis","volume":"37","author":"Desai C","year":"1989","unstructured":"Desai C, , Heera S, , Patel A, et al. Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. J Assoc Physicians India, 1989; 37(11):694\u2013697.","journal-title":"J Assoc Physicians India"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.194118"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.6b00051"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102850"},{"issue":"2","key":"e_1_3_5_56_2","first-page":"41","article-title":"Evaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis","volume":"42","author":"van der Werf T","year":"2016","unstructured":"van der Werf T, , Kosterink J, , Alffenaar J. Evaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis. Revisiting Co-Trimoxazole for the Treatment of Tuberculosis, 2016; 42(2):41.","journal-title":"Revisiting Co-Trimoxazole for the Treatment of Tuberculosis"},{"key":"e_1_3_5_57_2","first-page":"59","volume-title":"Revisiting Co-Trimoxazole for the Treatment of Tuberculosis","author":"Stienstra D","year":"2016","unstructured":"Stienstra D, , J WC. Trimethoprim\/sulfamethoxazole susceptibility of mycobacterium tuberculosis. In: Revisiting Co-Trimoxazole for the Treatment of Tuberculosis, vol. 42. University of Groningen; 2016, p. 59."},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01868-13"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501280-00008"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12070672"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2289-x"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0832-z"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9010719"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.6b01089"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.02.011"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq017"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1988"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02012-19"},{"issue":"6","key":"e_1_3_5_69_2","first-page":"939","article-title":"The early bactericidal activity of drugs in patients with pulmonary tuberculosis","volume":"121","author":"Jindani A","year":"1980","unstructured":"Jindani A, , Aber V, , Edwards E, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis, 1980; 121(6):939\u2013949.","journal-title":"Am Rev Respir Dis"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01378-08"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.013755"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02585-w"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/1791013a0"},{"issue":"1","key":"e_1_3_5_74_2","first-page":"3","article-title":"The antimycobacterial activity of B 663","volume":"36","author":"Barry V","year":"1965","unstructured":"Barry V, , Conalty M. The antimycobacterial activity of B 663. Lepr Rev, 1965; 36(1):3\u20137.","journal-title":"Lepr Rev"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02945619"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.5.615"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2004.04.001"},{"issue":"1","key":"e_1_3_5_79_2","first-page":"9","article-title":"Pharmacokinetics of clofazimine in healthy volunteers and its implications for the treatment regimen in patient","volume":"55","author":"Schaad-Lanyi Z","year":"1987","unstructured":"Schaad-Lanyi Z, , Dieterle W, , Dubois JP, et al. Pharmacokinetics of clofazimine in healthy volunteers and its implications for the treatment regimen in patient. Int J Lepr Other Mycobact Dis, 1987; 55(1):9\u201315.","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02565-14"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047494"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01207-2016"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02445-2016"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01897-12"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2020.10.008"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01144-22"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00186-22"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx152"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep34293"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03539-14"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.2816-2821.2005"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17030373"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612822666160128150636"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30148-1"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141895"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01124-13"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00046"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.112.967604"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31826c197f"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200072109"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2018.05.002"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2013.11.014"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-306"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126014"},{"key":"e_1_3_5_105_2","first-page":"1","article-title":"On the use and administration of cod-liver oil in pulmonary consumption","author":"Williams CJB","year":"1849","unstructured":"Williams CJB. On the use and administration of cod-liver oil in pulmonary consumption. Lond. Clin. Med. J, 1849:1\u201318.","journal-title":"Lond. Clin. Med. J"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2006.12.052"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138340"},{"key":"e_1_3_5_108_2","article-title":"The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion","volume":"1500","author":"Nursyam EW","year":"2006","unstructured":"Nursyam EW, , Amin Z, , Rumende CM. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Hemoglobin, 2006; 1500.","journal-title":"Hemoglobin"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200804-567OC"},{"key":"e_1_3_5_110_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-016-0208-y"},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.112.034967"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200701-007OC"},{"key":"e_1_3_5_113_2","doi-asserted-by":"publisher","DOI":"10.1086\/380451"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2000.1019"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03349038"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1996.11813100"},{"issue":"1","key":"e_1_3_5_117_2","first-page":"114","article-title":"The influence of vitamin D intake on serum calcium in tuberculosis","volume":"97","author":"Gwinup G","year":"1981","unstructured":"Gwinup G, , Randazzo G, , Elias A. The influence of vitamin D intake on serum calcium in tuberculosis. Acta Endocrinol (Copenh), 1981; 97(1):114\u2013117.","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"2","key":"e_1_3_5_118_2","first-page":"185","article-title":"Role of vitamin D in pulmonary Tuberculosis","volume":"32","author":"Narang N","year":"1994","unstructured":"Narang N, , Gupta R, , Jain M. Role of vitamin D in pulmonary Tuberculosis. J Assoc Physicians India, 1994; 32(2):185\u2013188.","journal-title":"J Assoc Physicians India"},{"issue":"5","key":"e_1_3_5_119_2","first-page":"157","article-title":"Vitamin D administration to tuberculous children and its value","volume":"137","author":"Morcos M","year":"1998","unstructured":"Morcos M, , Gabr A, , Samuel S, et al. Vitamin D administration to tuberculous children and its value. Boll Chim Farm, 1998; 137(5):157\u2013164.","journal-title":"Boll Chim Farm"},{"key":"e_1_3_5_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61889-2"},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-22"},{"key":"e_1_3_5_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60405-X"},{"issue":"1","key":"e_1_3_5_123_2","first-page":"119","article-title":"Influence of a single oral dose of vitamin D2 on serum 25-hydroxyvitamin D concentrations in tuberculosis patients","volume":"13","author":"Martineau A","year":"2009","unstructured":"Martineau A, , Nanzer A, , Satkunam K, et al. Influence of a single oral dose of vitamin D2 on serum 25-hydroxyvitamin D concentrations in tuberculosis patients. Int J Tuberc Lung Dis, 2009; 13(1):119\u2013125.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_5_124_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03360-5"},{"key":"e_1_3_5_125_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009885"},{"key":"e_1_3_5_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2018.04.003"},{"key":"e_1_3_5_127_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2795090"},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab964"},{"key":"e_1_3_5_129_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00652-17"},{"key":"e_1_3_5_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70110-X"},{"key":"e_1_3_5_131_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.1.184"},{"key":"e_1_3_5_132_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/147.5.1279"},{"key":"e_1_3_5_133_2","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200709001-00003"},{"key":"e_1_3_5_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(03)00358-4"},{"key":"e_1_3_5_135_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612823666161116114732"},{"key":"e_1_3_5_136_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2021.09.002"},{"key":"e_1_3_5_137_2","doi-asserted-by":"publisher","DOI":"10.1208\/pt060480"},{"key":"e_1_3_5_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.powtec.2016.09.053"},{"key":"e_1_3_5_139_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01066-6"},{"key":"e_1_3_5_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2007.06.006"},{"key":"e_1_3_5_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2016.03.024"},{"key":"e_1_3_5_142_2","doi-asserted-by":"publisher","DOI":"10.1080\/02652048.2018.1523970"},{"issue":"2","key":"e_1_3_5_143_2","first-page":"632","article-title":"Development of an excipient-free peptide dry powder inhalation for the treatment of pulmonary fibrosis","volume":"17","author":"Zhang Y","year":"2020","unstructured":"Zhang Y, , MacKenzie B, , Koleng JJ, et al. Development of an excipient-free peptide dry powder inhalation for the treatment of pulmonary fibrosis. Mol Pharm, 2020; 17(2):632\u2013644.","journal-title":"Mol Pharm"},{"key":"e_1_3_5_144_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12010055"},{"key":"e_1_3_5_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaerosci.2023.106290"},{"key":"e_1_3_5_146_2","doi-asserted-by":"publisher","DOI":"10.1086\/317524"},{"key":"e_1_3_5_147_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2004.19.2.167"},{"key":"e_1_3_5_148_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2008.06274.x"},{"key":"e_1_3_5_149_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl533"},{"key":"e_1_3_5_150_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.140201897"},{"key":"e_1_3_5_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2010.03.001"},{"key":"e_1_3_5_152_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12040387"},{"key":"e_1_3_5_153_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2016.05.031"},{"key":"e_1_3_5_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.05.065"},{"key":"e_1_3_5_155_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041238"},{"key":"e_1_3_5_156_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.6b00905"},{"key":"e_1_3_5_157_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-813687-4.00008-6"},{"key":"e_1_3_5_158_2","doi-asserted-by":"publisher","DOI":"10.1088\/1674-1056\/23\/8\/088102"},{"key":"e_1_3_5_159_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12070645"}],"container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jamp.2024.0051","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2024.0051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2024.0051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:11:49Z","timestamp":1777644709000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jamp.2024.0051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":158,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8,1]]}},"alternative-id":["10.1089\/jamp.2024.0051"],"URL":"https:\/\/doi.org\/10.1089\/jamp.2024.0051","relation":{},"ISSN":["1941-2711","1941-2703"],"issn-type":[{"value":"1941-2711","type":"print"},{"value":"1941-2703","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}